BLOG / 🇺🇸 United States · · daily

HHS & Healthcare Contracts Intelligence — March 21, 2026

HHS & Healthcare Contracts Intelligence

By Gunpowder Editorial ·

1 total filings analysed

Executive Summary

Spectral MD secured an $86.6M BARDA contract for burn wound imaging R&D, with $49.6M already outlayed on a 7-year deal potentially reaching $127.8M including options, signaling robust federal support for U.S. medtech innovation. This full-competition award to a small business underscores BARDA's commitment to preparedness tech amid high execution already.

Investors gain a bullish entry into niche biotech R&D with monitored long-term risks.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Tracking the trend? Catch up on the prior HHS & Healthcare Contracts Intelligence digest from March 14, 2026.

Investment Signals (1)

  • $86.6M BARDA R&D Award (HIGH)

    $86,574,404 obligated with $49,600,146 outlayed for burn imaging device; options add $41.2M upside to $127.8M total.

Risk Flags (1)

  • Execution [MEDIUM RISK]

    7-year term to 2030-09-30 vulnerable to funding cuts or R&D delays in NAICS 541714 biotech development.

Opportunities (1)

  • $41.2M unexercised options expandable via cost-plus fixed-fee structure.

Sector Themes (1)

  • Full-competition award for PSC 6525 imaging tech highlights federal priority on burn care innovation.

Watch List (1)

  • 👁

    {"entity"=>"Spectral MD, Inc.", "reason"=>"$49.6M outlays signal revenue ramp; $127.8M ceiling offers 47% growth potential.", "trigger"=>"Option exercises or Q1 2027 outlays >$60M"}

Get daily alerts with 1 investment signals, 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: HHS & Healthcare Contracts Intelligence

🇺🇸 More from United States

View all →